AbbVie sells senior notes in offering with about $7.95 billion in expected net proceeds
AbbVie agreed on February 24, 2026 to sell seven series of senior notes, with total principal of $8.0 billion, to a group of underwriters led by J.P. Morgan, BofA Securities, Morgan Stanley and Wells Fargo. The company expects net proceeds of about $7.95 billion, which it plans to use mainly to repay amounts outstanding under a $4.0 billion 364-day delayed draw term loan facility maturing in May 2026, of which $2.0 billion is currently outstanding.
Key points
- Seven series of senior notes with total principal of $8.0 billion, maturing from 2028 to 2066
- Expected net proceeds of about $7.95 billion after underwriting discounts and estimated offering expenses
- Proceeds planned to repay the $4.0 billion 364-day term loan, of which $2.0 billion is outstanding, and for general corporate purposes
- Closing expected March 4, 2026, subject to customary closing conditions
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.